The DOI matches its Crossref record.
Expression of hepatocyte growth factor and its receptor c- met proto-oncogene in hepatocellular carcinoma
Open accessAbstract
The c-met proto-oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF), a potent mitogen and motogen for epithelial cells. Because of its profound effects on cell growth and motility, HGF may be important in the development of cancer metastases in hepatocellular carcinoma (HCC). In this study, we examined HGF concentration and expression of the c-met-proto-oncogene product (c-met) in 62 patients with HCC to determine the relationship between the level of expression and clinicopathological features, and patient outcome following hepatectomy. Western blotting was used to examine the c-met expression, and HGF concentration in tumors was measured using an enzyme-linked immunosorbent assay. c-met was found to be overexpressed in HCC compared with nontumorous liver tissue (P < .01), and correlated with an increased incidence of intrahepatic metastases (P = .039). Patients were divided into two groups, low c-met HCC and high c-met HCC. Patients with high c-met HCC had a significantly shorter 5-year survival than patients with low c-met HCC (33.5% vs. 80.3%, respectively; P < .05). However, there was no correlation between HGF concentration in the tumor tissue and clinicopathological factors and patient survival. These results indicate that expression of c-met played an important role in tumor growth and metastases in patients who underwent hepatectomy for HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type
Yuneva, M. O., Fan, T. W. M., Allen, T. D., Higashi, R. M., Ferraris, D. V., Tsukamoto, T., Matés, J. M., Alonso, F. J., Wang, C., Seo, Y., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.015 · Cited by 639
Role of epithelial to mesenchymal transition in hepatocellular carcinoma
Giannelli, G., Koudelkova, P., Dituri, F., & Mikulits, W. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.007 · Cited by 615
Zhang, Y., Xia, M., Jin, K., Wang, S., Wei, H., Fan, C., Wu, Y., Li, X., Li, X., Li, G., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0796-y · Cited by 572
Genomics and Signaling Pathways in Hepatocellular Carcinoma
Villanueva, A., Newell, P., Chiang, D., Friedman, S., & Llovet, J. (2007) · Seminars in Liver Disease · doi:10.1055/s-2006-960171 · Cited by 556
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
Christensen, J. G., Burrows, J., & Salgia, R. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.09.044 · Cited by 513
Dysregulation of Wnt/β-Catenin Signaling in Gastrointestinal Cancers
White, B. D., Chien, A. J., & Dawson, D. W. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.001 · Cited by 469
Chen, R., Jiang, X., Sun, D., Han, G., Wang, F., Ye, M., Wang, L., & Zou, H. (2009) · Journal of Proteome Research · doi:10.1021/pr8008012 · Cited by 400
Kaposi-Novak, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27236 · Cited by 398
Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment
Zhou, F., Shang, W., Yu, X., & Tian, J. (2018) · Medicinal Research Reviews · doi:10.1002/med.21455 · Cited by 397
Hepatocellular Carcinoma-Cause, Treatment and Metastasis
Tang, Z.-Y. (2001) · World Journal of Gastroenterology · doi:10.3748/wjg.v7.i4.445 · Cited by 375
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Genetic mechanisms of hepatocarcinogenesis
Feitelson, M. A., Sun, B., Lale Satiroglu Tufan, N., Liu, J., Pan, J., & Lian, Z. (2002) · Oncogene · doi:10.1038/sj.onc.1205434 · Cited by 322
Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma
Dimri, M., & Satyanarayana, A. (2020) · Cancers · doi:10.3390/cancers12020491 · Cited by 311
Zhu, Z.-W., Friess, H., Wang, L., Abou-Shady, M., Zimmermann, A., Lander, A. D., Korc, M., Kleeff, J., & Büchler, M. W. (2001) · Gut · doi:10.1136/gut.48.4.558 · Cited by 291
Huynh, H., Nguyen, T. T. T., Chow, K.-H. K.-P., Tan, P. H., Soo, K. C., & Tran, E. (2003) · BMC Gastroenterology · doi:10.1186/1471-230x-3-19 · Cited by 289
Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer
Jiang, W. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(98)00019-5 · Cited by 264
Met as a therapeutic target in HCC: Facts and hopes
Giordano, S., & Columbano, A. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.009 · Cited by 158
The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control
Guégan, J.-P., Frémin, C., & Baffet, G. (2012) · International Journal of Hepatology · doi:10.1155/2012/328372 · Cited by 56
Tanaka, K., Kondoh, N., Shuda, M., Matsubara, O., Imazeki, N., Ryo, A., Wakatsuki, T., Hada, A., Goseki, N., Igari, T., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(01)00026-6 · Cited by 47
Metadata
- Authors
- Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H., & Okamoto, E.
- Venue
- Hepatology
- Published
- 1997-04
- Volume
- 25
- Issue
- 4
- Pages
- 862-866
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1979008189
- Cited by
- 226
- References
- 0
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.